GlassScriptPhysician profile
James Burdette Boyes
NPI 1962570713
$2,339.73
in general payments reported to CMS, 2019-2025
24 companies · $282 in 2025
The $282 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $878 · 2022: $386 · 2023: $422 · 2024: $371 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,075.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $557.51 | 2021-2025 | |
| Lilly USA, LLC | $402.23 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $211.80 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $203.25 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $157.50 | 2021-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.27 | 2021-2024 | Jardiance |
| Amgen INC. | $97.54 | 2024-2025 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $75.66 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $62.50 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $61.46 | 2022 | |
| Glaxosmithkline, LLC. | $53.90 | 2021-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Nestle Healthcare Nutrition INC. | $49.92 | 2021-2022 | |
| Amarin Pharma, INC. | $43.08 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.96 | 2021-2023 | Xifaxan |
| Daiichi Sankyo INC. | $23.84 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $21.21 | 2024 | Watchman Flx |
| Phathom Pharmaceuticals, INC. | $18.63 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $17.89 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.72 | 2022 | |
| Eisai INC. | $16.28 | 2022 | |
| Arbor Pharmaceuticals, INC. | $16.02 | 2021 | |
| Exact Sciences Corporation | $15.34 | 2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $14.96 | 2022 | |
| Endogastric Solutions, INC | $9.26 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Boyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.